Literature DB >> 34117077

Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure.

Qandeel H Soomro1, David M Charytan2.   

Abstract

Entities:  

Keywords:  cardiovascular disease; heart failure; hemodialysis; kidney failure; mineralocorticoid receptor antagonists

Mesh：

Substances：

Year:  2021        PMID： 34117077      PMCID： PMC8216618          DOI： 10.2215/CJN.04460421

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  10 in total

Review 1.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

2.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

3.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

4.  Aldosterone-receptor antagonism and end-stage renal disease.

Authors:  Niall McLaughlin; Todd W B Gehr; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

5.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

6.  Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.

Authors:  Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

7.  Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

Authors:  Nicola C Edwards; Richard P Steeds; Paul M Stewart; Charles J Ferro; Jonathan N Townend
Journal:  J Am Coll Cardiol       Date:  2009-08-04       Impact factor: 24.094

8.  Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.

Authors:  Eveline M Oestreicher; Diego Martinez-Vasquez; James R Stone; Larus Jonasson; Weranuj Roubsanthisuk; Koji Mukasa; Gail K Adler
Journal:  Circulation       Date:  2003-10-27       Impact factor: 29.690

9.  The relationship between Aldosterone level and various LV conditions in patients with End-stage renal disease.

Authors:  Vida Nesarhosseini; Hossein Mohsenipouya; Atieh Makhlough; Rozita Jalalian
Journal:  Caspian J Intern Med       Date:  2019

10.  Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.

Authors:  Kuan-Ting Chen; Yi-No Kang; Yen-Chung Lin; I-Lin Tsai; Wei-Chiao Chang; Te-Chao Fang; Mai-Szu Wu; Chih-Chin Kao
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-11       Impact factor: 10.614
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.